tiprankstipranks
Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
US Market
IMRX
Immuneering
RESEARCH TOOLSreports
Want to see IMRX full AI Analyst Report?

Immuneering (IMRX) Stock News & Sentiment

665 Followers
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
Premium
Company Announcements
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
15d ago
IMRX
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
1M ago
ANGX
IMRX
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts
2M ago
EVAX
IMRX
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts
2M ago
MWH
AKTS
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
Premium
Ratings
Advancing Atebimetinib Pipeline and Strong Cash Runway Underpin Buy Rating on Immuneering
2M ago
IMRX
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
Premium
Ratings
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang
4M ago
IMRX
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
Premium
Company Announcements
Immuneering Reports Strong Phase 2a Pancreatic Cancer Survival Data
5M ago
8K
IMRX
More IMRX News >

IMRX News on the Web

Immuneering (IMRX) Gets a Buy from Chardan Capital
TipRanks News
Bullish
Is Immuneering (IMRX) Undervalued After Q1 2026 Earnings? EPS -0.21 Beats -0. ...
GuruFocus News
Neutral
Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)
TipRanks News
Bullish
Is Immuneering (IMRX) Overvalued After Q1 2026 EPS Beat? EPS -0.21 vs -0.26 est. ...
GuruFocus News
Neutral
Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)
TipRanks News
Neutral
Immuneering reports Q1 EPS (21c), consensus (25c)
TipRanks News
Bullish
Immuneering (IMRX) Reports Q1 Earnings, Beats Expectations
GuruFocus News
Bullish
Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
IMRX
Sector Average
Media Buzz
This Week5 articles
Weekly Average3.5 articles
News Sentiment
This Week99%
Sector Average79%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IMRX’s Media Buzz Sentiment?
5 articles about IMRX were published this week. In an average week, 3.5 articles are published.
    What is IMRX’s weekly average amount of articles?
    In an average week, 3.5 articles about IMRX are published.
      What is IMRX’s News Sentiment?
      99% of articles about IMRX were positive this week, compared to its sector average of 79%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        JUNSJupiter Neurosciences, Inc.
        Showing the stocks with the most bullish news sentiment over the past week